Refine
Has Fulltext
- yes (26)
Is part of the Bibliography
- yes (26)
Year of publication
- 2022 (26) (remove)
Document Type
- Journal article (26) (remove)
Keywords
- depression (3)
- active zone (2)
- anxiety (2)
- coping (2)
- fMRI (2)
- pharmacovigilance (2)
- schizophrenia (2)
- therapeutic drug monitoring (2)
- Alzheimer’s dementia (1)
- Alzheimer’s disease (1)
- BDNF (1)
- Big Five (1)
- Brain atrophy (1)
- CA3 (1)
- CA4 (1)
- CAPS (1)
- COVID-19 (1)
- Chronic heart failure (1)
- Cognitive decline (1)
- Covid-19 (1)
- Fibromyalgia syndrome (1)
- GFAP (1)
- GPCRs (1)
- Glial fibrillary acidic protein (1)
- HDBSCAN (1)
- Htr1a (1)
- Htr2a (1)
- Htr2c (1)
- Memory dysfunction (1)
- MiMIC (1)
- Npy (1)
- Npyr1 (1)
- Npyr2 (1)
- PTSD (1)
- Pharmakovigilanz (1)
- Psychopharmakotherapie (1)
- Qualitätssicherung (1)
- RIM1α (1)
- Rotary EXcitation (REX) (1)
- STORM (1)
- SV pool (1)
- Therapeutisches Drug Monitoring (1)
- Unc-13 (1)
- acute brain slices (1)
- adverse drug reactions (1)
- age (1)
- age stereotypes (1)
- antidepressant (1)
- biased signaling (1)
- children (1)
- clinical practice guideline (1)
- cognitive decline (1)
- cognitive impairment (1)
- cohort studies (1)
- coping style (1)
- cross-sectional studies (1)
- dementia (1)
- dementia with Lewy bodies (1)
- dentate gyrus (1)
- diagnostic medicine (1)
- disability (1)
- dual guidance (1)
- early-onset predictors (1)
- ectodomain cleavage (1)
- egoism (1)
- electron tomography (1)
- family caregivers (1)
- fear expression (1)
- fibromyalgia (1)
- functional magnetic resonance imaging (1)
- gene (1)
- gene expression (1)
- heart failure (1)
- hierarchical drift-diffusion modeling (1)
- high-pressure freezing (1)
- hippocampal mossy fiber bouton (1)
- hippocampus (1)
- incentives (1)
- informal caregiving (1)
- life events (1)
- localization microscopy (1)
- loneliness (1)
- longitudinal studies (1)
- maternal (1)
- matrix metalloproteinase (1)
- mental health (1)
- midbrain (1)
- migraine (1)
- mild cognitive impairment (1)
- motivation (1)
- multi‑center cohort study (1)
- nanoarchitecture (1)
- negative affect (1)
- neurodegeneration (1)
- neurofilament light chain (1)
- neuromelanin granules (1)
- neuron (1)
- neuropathic pain (1)
- nurses (1)
- older employees (1)
- oligodendrocyte (1)
- oscillating biomagnetic fields (1)
- pain (1)
- parathyroid hormone 1 receptor (1)
- paternal (1)
- peripartum (1)
- phosphorylated tau protein (1)
- physical health (1)
- polygenic risk score (1)
- population-based studies (1)
- positive affect (1)
- postmortem (1)
- postnatal depression (1)
- pregnancy (1)
- presynaptic (1)
- presynaptic homeostasis (1)
- prevention (1)
- prosociality (1)
- proteomics (1)
- psychopharmacotherapy (1)
- psychotropic medications (1)
- qualitative approaches (1)
- quality assurance (1)
- rare diseases (1)
- religiosity (1)
- renal function (1)
- risperidone (1)
- serum concentration (1)
- social anxiety (1)
- social avoidance (1)
- social decision-making (1)
- social distancing (1)
- social isolation (1)
- social motives (1)
- social neuroscience (1)
- stereology (1)
- stress (1)
- stress granules (1)
- substantia nigra pars compacta (1)
- supervisors (1)
- synaptic ultrastructure (1)
- systematic review (1)
- ultrasound imaging (1)
- unerwünschte Arzneimittelwirkungen (1)
- younger employees (1)
Institute
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (26) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 232944 (1)
Objective
Alzheimer’s disease (AD) is a growing challenge worldwide, which is why the search for early-onset predictors must be focused as soon as possible. Longitudinal studies that investigate courses of neuropsychological and other variables screen for such predictors correlated to mild cognitive impairment (MCI). However, one often neglected issue in analyses of such studies is measurement invariance (MI), which is often assumed but not tested for. This study uses the absence of MI (non-MI) and latent factor scores instead of composite variables to assess properties of cognitive domains, compensation mechanisms, and their predictability to establish a method for a more comprehensive understanding of pathological cognitive decline.
Methods
An exploratory factor analysis (EFA) and a set of increasingly restricted confirmatory factor analyses (CFAs) were conducted to find latent factors, compared them with the composite approach, and to test for longitudinal (partial-)MI in a neuropsychiatric test battery, consisting of 14 test variables. A total of 330 elderly (mean age: 73.78 ± 1.52 years at baseline) were analyzed two times (3 years apart).
Results
EFA revealed a four-factor model representing declarative memory, attention, working memory, and visual–spatial processing. Based on CFA, an accurate model was estimated across both measurement timepoints. Partial non-MI was found for parameters such as loadings, test- and latent factor intercepts as well as latent factor variances. The latent factor approach was preferable to the composite approach.
Conclusion
The overall assessment of non-MI latent factors may pose a possible target for this field of research. Hence, the non-MI of variances indicated variables that are especially suited for the prediction of pathological cognitive decline, while non-MI of intercepts indicated general aging-related decline. As a result, the sole assessment of MI may help distinguish pathological from normative aging processes and additionally may reveal compensatory neuropsychological mechanisms.
Dementia, including Alzheimer's disease, is a growing problem worldwide. Prevention or early detection of the disease or a prodromal cognitive decline is necessary. By means of our long-term follow-up ‘Vogel study’, we aim to predict the pathological cognitive decline of a German cohort (mean age was 73.9 ± 1.55 years at first visit) with three measurement time points within 6 years per participant. Especially in samples of the elderly and subjects with chronic or co-morbid diseases, dropouts are one of the biggest problems of long-term studies. In contrast to the large number of research articles conducted on the course of dementia, little research has been done on the completion of treatment. To ensure unbiased and reliable predictors of cognitive decline from study completers, our objective was to determine predictors of dropout. We conducted multivariate analyses of covariance and multinomial logistic regression analyses to compare and predict the subject's dropout behaviour at the second visit 3 years after baseline (full participation, partial participation and no participation/dropout) with neuropsychiatric, cognitive, blood and lifestyle variables. Lower performance in declarative memory, attention and visual–spatial processing predicted dropout rather than full participation. Lower performance in visual–spatial processing predicted partial participation as opposed to full participation. Furthermore, lower performance in mini-mental status examination predicted whether subjects dropped out or participated partially instead of full participation. Baseline cognitive parameters are associated with dropouts at follow-up with a loss of impaired participants. We expect a bias into a healthier sample over time.
To slow down the spread of the SARS-Cov-2 virus, countries worldwide severely restricted public and social life. In addition to the physical threat posed by the viral disease (COVID-19), the pandemic also has implications for psychological well-being. Using a small sample (N = 51), we examined how Big Five personality traits relate to coping with contact restrictions during three consecutive weeks in the first wave of the COVID-19 pandemic in Germany. We showed that extraversion was associated with suffering from severe contact restrictions and with benefiting from their relaxation. Individuals with high neuroticism did not show a change in their relatively poor coping with the restrictions over time, whereas conscientious individuals seemed to experience no discomfort and even positive feelings during the period of contact restrictions. Our results support the assumption that neuroticism is a vulnerability factor in relation to psychological wellbeing but also show an influence of contact restrictions on extraverted individuals.
Decreased oligodendrocyte number in hippocampal subfield CA4 in schizophrenia: a replication study
(2022)
Hippocampus-related cognitive deficits in working and verbal memory are frequent in schizophrenia, and hippocampal volume loss, particularly in the cornu ammonis (CA) subregions, was shown by magnetic resonance imaging studies. However, the underlying cellular alterations remain elusive. By using unbiased design-based stereology, we reported a reduction in oligodendrocyte number in CA4 in schizophrenia and of granular neurons in the dentate gyrus (DG). Here, we aimed to replicate these findings in an independent sample. We used a stereological approach to investigate the numbers and densities of neurons, oligodendrocytes, and astrocytes in CA4 and of granular neurons in the DG of left and right hemispheres in 11 brains from men with schizophrenia and 11 brains from age- and sex-matched healthy controls. In schizophrenia, a decreased number and density of oligodendrocytes was detected in the left and right CA4, whereas mean volumes of CA4 and the DG and the numbers and density of neurons, astrocytes, and granular neurons were not different in patients and controls, even after adjustment of variables because of positive correlations with postmortem interval and age. Our results replicate the previously described decrease in oligodendrocytes bilaterally in CA4 in schizophrenia and point to a deficit in oligodendrocyte maturation or a loss of mature oligodendrocytes. These changes result in impaired myelination and neuronal decoupling, both of which are linked to altered functional connectivity and subsequent cognitive dysfunction in schizophrenia.
Neuromelanin granules (NMGs) are organelle-like structures present in the human substantia nigra pars compacta. In addition to neuromelanin, NMGs contain proteins, lipids and metals. As NMG-containing dopaminergic neurons are preferentially lost in Parkinson’s disease and dementia with Lewy bodies (DLB), it is assumed that NMGs may play a role in neurodegenerative processes. Until now, this role is not completely understood and needs further investigation. We therefore set up an exploratory proteomic study to identify differences in the proteomic profile of NMGs from DLB patients (n = 5) compared to healthy controls (CTRL, n = 5). We applied a laser microdissection and mass-spectrometry-based approach, in which we used targeted mass spectrometric experiments for validation. In NMG-surrounding (SN\(_{Surr.}\)) tissue of DLB patients, we found evidence for ongoing oxidative damage and an impairment of protein degradation. As a potentially disease-related mechanism, we found α-synuclein and protein S100A9 to be enriched in NMGs of DLB cases, while the abundance of several ribosomal proteins was significantly decreased. As S100A9 is known to be able to enhance the formation of toxic α-synuclein fibrils, this finding points towards an involvement of NMGs in pathogenesis, however the exact role of NMGs as either neuroprotective or neurotoxic needs to be further investigated. Nevertheless, our study provides evidence for an impairment of protein degradation, ongoing oxidative damage and accumulation of potentially neurotoxic protein aggregates to be central mechanisms of neurodegeneration in DLB.
Risperidone is commonly used to treat different psychiatric disorders worldwide. Knowledge on dose–concentration relationships of risperidone treatment in children and adolescents with schizophrenia or other psychotic disorders is, however, scarce and no age-specific therapeutic ranges have been established yet. Multicenter data of a therapeutic drug monitoring service were analyzed to evaluate the relationship between risperidone dose and serum concentration of the active moiety (risperidone (RIS) plus its main metabolite 9-hydroxyrisperidone (9-OH-RIS)) in children and adolescents with psychotic disorders. Patient characteristics, doses, serum concentrations and therapeutic outcomes were assessed by standardized measures. The study also aimed to evaluate whether the therapeutic reference range for adults (20–60 ng/ml) is applicable for minors. In the 64 patients (aged 11–18 years) included, a positive correlation between daily dose and the active moiety (RIS\(_{am}\)) concentration was found (r\(_s\) = 0.49, p = 0.001) with variation in dose explaining 24% (r\(_s\)\(^2\) = 0.240) of the variability in serum concentrations. While the RIS\(_{am}\) concentration showed no difference, RIS as well 9-OH-RIS concentrations and the parent to metabolite ratio varied significantly in patients with co-medication of a CYP2D6 inhibitor. Patients with extrapyramidal symptoms (EPS) had on average higher RIS\(_{am}\) concentrations than patients without (p = 0.05). Considering EPS, the upper threshold of the therapeutic range of RIS\(_{am}\) was determined to be 33 ng/ml. A rough estimation method also indicated a possibly decreased lower limit of the preliminary therapeutic range in minors compared to adults. These preliminary data may contribute to the definition of a therapeutic window in children and adolescents with schizophrenic disorders treated with risperidone. TDM is recommended in this vulnerable population to prevent concentration-related adverse drug reactions.